Effectiveness and Safety of First-Line Non-Bismuth Quadruple Concomitant Therapy Versus Single-Capsule Bismuth Quadruple Therapy.
Nyssen OP, Montes N, Pérez-Aísa Á, Martínez-Domínguez SJ, Tejedor-Tejada J, Lucendo AJ, Huguet JM, Garre A, Bujanda L, Pabón-Carrasco M, Castro-Fernández M, Perona M, Ortiz-Polo I, Núñez Ó, Marcos MS, Gómez Rodríguez BJ, Loro AM, Bermejo F, Barrio J, Iyo E, Alonso EB, Flores V, Keco-Huerga A, Mata-Romero P, Gomez-Camarero J, Fernández-Bermejo M, Cajal MD, Martin-Holgado D, Velayos B, Planella M, Alcaide N, Blanco ABP, Fernández-Salazar L, Pajares Villarroya R, Alonso MS, Mejide PP, Jiménez-Moreno M, Perelló A, Pascual-Mato M, Albéniz E, Hernández G, Gonzalez MF, Sanchez SM, de Castro JDF, Cano-Català A, Parra P, Moreira L, Mégraud F, O'Morain C, Gisbert JP; Hp‐EuReg investigators.
Nyssen OP, et al. Among authors: marcos ms.
Aliment Pharmacol Ther. 2025 Jul 4. doi: 10.1111/apt.70261. Online ahead of print.
Aliment Pharmacol Ther. 2025.
PMID: 40616238